ADAM17 and central nervous system cancer: Several studies reported that ADAM9, ADAM10, and ADAM17 showed high expression in glioma; meanwhile, ADAM9, as a potential regulator of glioma invasion, showed higher expression in GBM compared with LGG (17–19).